Skip To Main Content
Le contenu de ce site web est exclusivement réservé aux professionnels de santé en Belgique et au Luxembourg.
Campus
  • Articles
  • Éducation
Campus
  • Articles
  • Éducation

L’engagement de Sanofi dans le carcinome épidermoïde cutané avancé

Depuis fin 2018, Sanofi offre de nouvelles perspectives de vie à plus de 200 patients atteints d’un carcinome épidermoïde cutané (CEC) avancé grâce à la mise en place d’un programme d’accès précoce à son traitement.

Découvrez l’engagement de Sanofi dans cette vidéo.

Articles liés
Underneath the skin

Underneath the Skin: Hidden Challenges of Uncontrolled AD and PN

What are the hidden challenges of living with uncontrolled Atopic Dermatitis (AD) and Prurigo Nodularis (PN)?

Explorer
Advancing the treatment: Meeting the challenge of uncontrolled Atopic Dermatitis (AD) and Prurigo Nodularis (PN)

Advancing Treatment for Uncontrolled AD and PN: New Approaches

As we continue to advance in our understanding and treatment capabilities, our response to uncontrolled AD and PN becomes more effective, paving the way for a future where patients can lead healthier, more comfortable lives8.

Explorer
Lipid management in patients with diabetes mellitus

Lipid management in patients with diabetes mellitus

Key principles of lipid management (LDL-C in particular) in accordance with the 2019 ESC/EAS Guidelines for the management of dyslipidaemias, and the 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.

Explorer
Sanofi Belgium - MAT-BE-2100417 – 06/2021